Portal de investigação
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Razaghizad, A
- Ni, JY
- Marques, P
- Mavrakanas, TA
- Tsoukas, MA
- Possik, E
- Huynh, T
- Edwards, JD
- Liu, P
- Swardfager, W
- Baroz, F
- Sharma, A
Unidades de investigação
Abstract
Aim: To identify unique clinical phenotypes in type 2 diabetes (T2D) and investigate their treatment response to canagliflozin using latent class analysis. Methods: This was a pooled latent class analysis of the individuals in the CANVAS Program and CREDENCE trial. The co-primary endpoints were hospitalization for heart failure (HHF) and the composite of cardiovascular death (CVD) or HHF. Secondary endpoints included three-point major adverse CV events, its individual components, and all-cause mortality. We completed Cox proportional hazards models to evaluate the effect of canagliflozin across phenotypes. Results: Four distinct phenotypes were identified: Phenotype 1 (n = 966, 6.6%), with the lowest prevalence of heart failure, kidney dysfunction and hypertension; Phenotype 2 (n = 4169, 28.7%), primarily comprising females with a high prevalence of atherosclerotic vascular disease (ASCVD); Phenotype 3 (n = 7108, 48.9%), predominately males with a high prevalence of ASCVD; and Phenotype 4 (n = 2300, 15.8%), possessing the highest prevalences of HF and renal dysfunction. A hierarchical increase in the risk of the primary endpoint was observed across the phenotypes, with the highest CV risk observed for Phenotype 4 (hazard ratio for HHF: 7.57 [95% CI: 4.19-13.69]). Canagliflozin significantly reduced HHF and the composite CVD or HHF across phenotypes (all P values for interaction > .05). Conclusion: We identified four clinically distinct T2D phenotypes with differential CV risks. Canagliflozin reduced the risk of CV events, irrespective of the phenotype, emphasizing its broad therapeutic acceptability.
Dados da publicação
- ISSN/ISSNe:
- 1463-1326, 1462-8902
- Tipo:
- Article
- Páginas:
- 5025-5035
- DOI:
- 10.1111/dom.15768
- Link para outro recurso:
- www.scopus.com
DIABETES OBESITY & METABOLISM Wiley-Blackwell Publishing Ltd
Documentos
- Não há documentos
Filiações
Keywords
- cardiovascular events; heart failure; SGLT2 inhibitors; type 2 diabetes
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Razaghizad A,Ni JY,Marques P,Mavrakanas TA,Tsoukas MA,Possik E,Huynh T,Edwards JD,Liu P,Swardfager W,Baroz F,Ferreira JP,Sharma A. Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial. Diabetes Obes. Metab. 2024. 26. (11):p. 5025-5035. IF:5,800. (1).
